Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice

E. Boven, M. M. Nauta, H. M M Schluper, F. Elferink, W. J F Van Der Vijgh, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1253-1260
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number10
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice'. Together they form a unique fingerprint.

Cite this